Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences
Abstract Background We consider two key challenges that early-stage biotechnology firms face in developing a sustainable financing strategy and a sustainable business model: developing a valuation model for drug compounds, and choosing an appropriate...
| Main Authors: | , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
BioMed Central
2023
|
| Online Access: | https://hdl.handle.net/1721.1/152279 |